Pediatric asthma: An unmet need for more effective, focused treatments. Issue 1 (15th November 2018)

• Record Type: Journal Article
• Authors: Papadopoulos, Nikolaos G.; Čustović, Adnan; Cabana, Michael D.; Dell, Sharon D.; Deschildre, Antoine; Hedlin, Gunilla; Hossny, Elham; Le Souëf, Peter; Matricardi, Paolo M.; Nieto, Antonio; Phipatanakul, Wanda; Pitrez, Paulo M.; Pohunek, Petr; Gavornikova, Marcela; Jaumont, Xavier; Price, David B.
• Editors: Kalayci, Ömer
• Is Part Of: Pediatric allergy and immunology. Volume 30:Issue 1(2019)
• Page Start: 7
• Page End: 16
• Publication Date: 2018-11-15
• Subjects: asthma management -- omalizumab -- pediatric asthma -- unmet need; Allergy in children -- Periodicals; Immunologic diseases in children -- Periodicals; 617
• DOI: 10.1111/pai.12990
• Languages: English
• ISSNs: 0905-6157

Abstract

Abstract: Background: Despite remarkable advances in our understanding of asthma, there are still several unmet needs associated with the management of pediatric asthma. Methods: A two‐day, face‐to‐face meeting was held in London, United Kingdom, on October 28 and 29, 2017, involving a group of international expert clinicians and scientists in asthma management to discuss the challenges and unmet needs that remain to be addressed in pediatric asthma. Results: These unmet needs include a lack of clinical efficacy and safety evidence, and limited availability of non‐steroid‐based alternative therapies in patients <6 years of age. An increased focus on children is needed in the context of clinical practice guidelines for asthma; current pediatric practice relies mostly on extrapolations from adult recommendations. Furthermore, no uniform definition of pediatric asthma exists, which hampers timely and robust diagnosis of the condition in affected patients. Conclusions: There is a need for a uniform definition of pediatric asthma, clearly distinguishable from adult asthma. Furthermore, guidelines which provide specific treatment recommendations for the management of pediatric asthma are also needed. Clinical trials and real‐world evidence studies assessing anti‐immunoglobulin E (IgE) therapies and other monoclonal antibodies in children <6 years of age with asthma may provide further information regarding the most appropriate treatment options in these vulnerable patients. Early intervention with anti‐IgE and non‐steroid‐based alternative therapies may delay disease progression, leading to improved clinical outcomes.